Voyageur Pharmaceuticals Ltd. (CVE:VM - Get Free Report) shares shot up 20% on Friday . The stock traded as high as C$0.36 and last traded at C$0.33. 756,632 shares traded hands during mid-day trading, an increase of 289% from the average session volume of 194,539 shares. The stock had previously closed at C$0.28.
Voyageur Pharmaceuticals Stock Up 23.6%
The firm's fifty day moving average is C$0.19 and its 200-day moving average is C$0.16. The company has a current ratio of 0.10, a quick ratio of 0.84 and a debt-to-equity ratio of 4.23. The stock has a market capitalization of C$51.52 million, a P/E ratio of -31.80 and a beta of 0.32.
About Voyageur Pharmaceuticals
(
Get Free Report)
Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in the acquiring, exploring, and developing raw materials for pharmaceutical products, primarily in the province of British Columbia, Canada, and the state of Utah. The company develops barium and iodine-based APIs. The company was formerly known as Voyageur Minerals Ltd.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Voyageur Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyageur Pharmaceuticals wasn't on the list.
While Voyageur Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
